全文获取类型
收费全文 | 93篇 |
免费 | 11篇 |
专业分类
基础医学 | 4篇 |
临床医学 | 2篇 |
内科学 | 57篇 |
神经病学 | 1篇 |
预防医学 | 2篇 |
药学 | 3篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 3篇 |
2020年 | 1篇 |
2019年 | 6篇 |
2018年 | 2篇 |
2016年 | 4篇 |
2015年 | 8篇 |
2014年 | 6篇 |
2013年 | 2篇 |
2012年 | 4篇 |
2011年 | 5篇 |
2010年 | 1篇 |
2009年 | 2篇 |
2008年 | 6篇 |
2007年 | 6篇 |
2006年 | 4篇 |
2005年 | 4篇 |
2004年 | 6篇 |
2003年 | 4篇 |
2002年 | 4篇 |
2001年 | 4篇 |
2000年 | 5篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1997年 | 3篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1992年 | 3篇 |
1991年 | 1篇 |
排序方式: 共有104条查询结果,搜索用时 15 毫秒
1.
C. Banella M. Ginevrino G. Catalano E. Fabiani G. Falconi M. Divona P. Curzi P. Panetta M.T. Voso N.I. Noguera 《Hematology/oncology and stem cell therapy》2021,14(2):163-168
FGFR–TACC, found in different tumor types, is characterized by the fusion of a member of fibroblast grown factor receptor (FGFR) tyrosine kinase (TK) family to a member of the transforming acidic coiled-coil (TACC) proteins. Because chromosome numerical alterations, hallmarks of FGFR–TACC fusions are present in many hematological disorders and there are no data on the prevalence, we studied a series of patients with acute myeloid leukemia and myelodysplastic syndrome who presented numerical alterations using cytogenetic traditional analysis. None of the analyzed samples showed FGFR3–TACC3 gene fusion, so screening for this mutation at diagnosis is not recommended. 相似文献
2.
3.
Emanuele Angelucci Valeria Santini Anna Angela Di Tucci Giulia Quaresmini Carlo Finelli Antonio Volpe Giovanni Quarta Flavia Rivellini Grazia Sanpaolo Daniela Cilloni Flavia Salvi Giovanni Caocci Alfredo Molteni Daniele Vallisa Maria Teresa Voso Susanna Fenu Lorenza Borin Giancarlo Latte Giuliana Alimena Sergio Storti Alfonso Piciocchi Paola Fazi Marco Vignetti Sante Tura 《European journal of haematology》2014,92(6):527-536
4.
Licia Iaccarino Tiziana Ottone Valentina Alfonso Laura Cicconi Mariadomenica Divona Serena Lavorgna Serena Travaglini Aleandra Ferrantini Giulia Falconi Constance Baer Monica Usai Fabio Forghieri Adriano Venditti Maria Ilaria Del Principe William Arcese Maria Teresa Voso Torsten Haferlach Francesco Lo-Coco 《American journal of hematology》2019,94(10):1091-1097
Despite the high probability of cure of patients with acute promyelocytic leukemia (APL), mechanisms of relapse are still largely unclear. Mutational profiling at diagnosis and/or relapse may help to identify APL patients needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene-panel, we tested BM samples of 44 APLs at the time of diagnosis, and of 31 at relapse. Mutations in PML and RARA genes were studied using a customized-NGS-RNA panel. Patients relapsing after ATRA-chemotherapy rarely had additional mutations (P = .009). In patients relapsing after ATRA/ATO, the PML gene was a preferential mutation target. We then evaluated the predictive value of mutations at APL diagnosis. A median of two mutations was detectable in 9/11 patients who later relapsed, vs one mutation in 21/33 patients who remained in CCR (P = .0032). This corresponded to a significantly lower risk of relapse in patients with one or less mutations (HR 0.046; 95% CI 0.011-0.197; P < .0001). NGS-analysis at the time of APL diagnosis may inform treatment decisions, including alternative treatments for cases with an unfavorable mutation profile. 相似文献
5.
6.
Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes 下载免费PDF全文
Death-associated protein kinase (DAP-kinase), a proapoptotic serine/threonine kinase, is a candidate tumor suppressor gene. We studied the methylation status of DAP-kinase of 194 bone marrow samples from 160 patients with acute myeloid leukemia (AML) and 34 with a myelodysplastic syndrome (MDS) at the time of initial diagnosis by polymerase chain reaction (PCR). Hypermethylation of DAP-kinase was present in 27.5% (44 of 160) of AML and in 47% (16 of 34) of MDS specimens and significantly correlated to loss of DAP-kinase expression (P =.008). It was significantly more frequent in AML secondary to therapy for other malignancies (s-AML; 14 of 29, 48.3%), as compared to de novo AML (30 of 131, 22.9%, P =.01). DAP-kinase hypermethylation in AML was associated with myelodysplastic changes in the bone marrow at the time of the initial diagnosis (P =.002) and with the presence of cytogenetic abnormalities (P =.02). Alteration in the apoptotic response due to the loss of DAP-kinase function may be an early event in the transformation pathway to secondary leukemia via myelodysplasia. 相似文献
7.
Genomic analysis of therapy‐related acute promyelocytic leukemias arising after malignant and non‐malignant disorders 下载免费PDF全文
8.
Caterina Tatarelli Anna Lina Piccioni Luca Maurillo Virginia Naso Roberta Battistini Mariella D’Andrea Marianna Criscuolo Carolina Nobile Nicoletta Villivà Stefano Mancini Benedetta Neri Massimo Breccia Susanna Fenu Francesco Buccisano Maria Teresa Voso Roberto Latagliata Maria Antonietta Aloe Spiriti 《Annals of hematology》2014,93(8):1413-1420
Myelodysplastic syndromes (MDS) are common in elderly patients. Recombinant human erythro-poietin (rHuEPO) has been widely used to treat anemia in lower risk MDS patients, but few data are known about rHuEPO treatment in the very elderly patient group. In order to investigate the role of rHuEPO treatment in terms of response, overall survival (OS), and toxicity in a very elderly MDS patient group, 93 MDS patients treated with rHuEPO when aged ≥80 years were selected among MDS cases enrolled in a retrospective multicenter study by the cooperative group Gruppo Romano Mielodisplasie (GROM) from Jan 2002 to Dec 2010. At baseline, median age was 82.7 (range 80–99.1) with a median hemoglobin (Hb) level of 9 g/dl (range 6–10.8). The initial dose of rHuEPO was standard (epoetin alpha 40,000 IU/week or epoetin beta 30,000 IU/week) in 59 (63.4 %) pa-tients or high in 34 (36.6 %) (epoetin alpha 80,000 IU/week) patients. We observed an erythroid response (ER) in 59 (63.4 %) patients. No thrombotic event was reported. Independent predictive factors for ER were low transfusion requirement before treatment (p?=?0.004), ferritin <200 ng/ml (p?=?0.017), Hb >8 g/dl (p?=?0.034), and a high-dose rHuEPO treatment (p?=?0.032). Median OS from rHuEPO start was 49.3 months (95 % CI 27.5–68.4) in responders versus 30.6 months (95 % CI 7.3–53.8) in resistant patients (p?=?0.185). In conclusion, rHuEPO treatment is safe and effective also in the very elderly MDS patients. However, further larger studies are warranted to evaluate if EPO treatment could be worthwhile in terms of quality of life and cost-efficacy in very old patients. 相似文献
9.
BACKGROUND: Health effects of occupational exposure to benzene are currently a problem, despite the fact that preventive measures have been in existence in Italy for more than 40 years. OBJECTIVES: To describe three recent cases of severe haematological disease presumably induced by an occupational exposure to benzene. Exposure occurred as a result of contact with ordinary automobile petrol used as a solvent-degreaser for metal parts. METHODS: Clinical diagnosis was performed using standard immuno-phenotypic and morphological criteria; the hypothesis of an occupational origin was derived from analysis of the occupational histories. RESULTS: The first case was a 59 year-old blacksmith suffering from acute myeloid leukaemia (AML) FAB M2, who had used petrol for 36 years to degrease the forged metal parts before painting them. The second was a 53 year-old mechanic with AML FAB M3 who had used petrol for 15 years to degrease mechanical parts of tanker motors. The third was an 82 year-old car mechanic suffering from idiopathic myelofibrosis since the age of 75, who had used petrol to degrease mechanical car motor parts for 42 years. In all three cases, the environmental hygiene measures necessary to limit inhalation or skin contact were not followed and, at times, in the case of the two mechanics, the petrol was siphoned by mouth; so there was substantial exposure to the 1-5% benzene present in the petrol. Latency of the disease was between 30-50 years from start of exposure, and between 3-17 years following cessation of exposure. CONCLUSION: The cases described indicate that the myelotoxic effects of benzene are still a problem. They were the consequence of improper use of petrol, due to total misinformation of the risks involved in such use. It is not possible to ascertain whether the cases presented are a casual aggregation or if the use of petrol as a solvent is more common than is normally believed; in the latter case two questions must be asked: is a "normal" occupational history able to discover such an uncommon risky condition of exposure? If it cannot, how many cases of benzene-related diseases escape aetiological diagnosis? It is not possible to provide precise answers but efforts should be made to improve the quality of information about the risks of petrol. Furthermore, in all cases of haematological disease potentially related to benzene, any form of contact with petrol, even if uncommon, should be carefully researched. 相似文献
10.